Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Liposomal Doxorubicin Combined with Vinorelbine in the Treatment of Advanced Metastatic Breast Cancer: a Single-Center, Prospective Phase II Clinical Study

NCT06653972 is registered in ClinicalTrials.gov with Wang Jiayu as lead sponsor.

NCT NCT06653972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06653972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Liposomal Doxorubicin Combined with Vinorelbine in the Treatment of Advanced Metastatic Breast Cancer: a Single-Center, Prospective Phase II Clinical Study
Lead sponsor
Wang Jiayu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2024
Completion date
September 30, 2026
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative metastatic breast cancer, liposomal doxorubicin, vinorelbine